

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
04 APR 12 PM 3:56

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The Duberstein Group, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 2100 Pennsylvania Ave, NW Ste 500 City Washington State/Zip (or Country) DC 20037 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name John W. Angus, III		Telephone 202-728-1100	E-mail (optional) _____
5. Senate ID # _____			6. House ID # 31811044
7. Client Name <input type="checkbox"/> Self Pfizer Inc.			_____

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$60,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____ Date 2/17/2004

Printed Name and Title John W. Angus, III - Senior Vice President & GC Pag

Registrant Name: **The Duberstein Group, Inc.**

Client Name: **Pfizer Inc.**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code GOV (one per page)

16. Specific Lobbying issues

S.1115 , Ban Asbestos in America Act of 2003, Asbestos Trust Fund

S.1125 , FAIR Act of 2003

Fairness in Asbestos Injury Resolution Act of 2003, Asbestos Trust Fund

S.413 , Asbestos Claims Criteria and Compensation Act of 2003, Asbestos Trust Fund

17. House(s) of Congress and Federal agencies contacted

Check if None

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Angus, III, John W.	
Berman, Michael S.	
Champlin, Steven M.	
Gandy, Henry M.	
Meyer, Daniel	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 2/17/2004

Printed Name and Title John W. Angus, III - Senior Vice President & GC Pag

Registrant Name: The Duberstein Group, Inc.

Client Name: Pfizer Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R.1 , Medicare Prescription Drug and Modernization Act of 2003, Medicare prescription drug benefit; rein of prescription drugs

H.R.2473 , Medicare Prescription Drug and Modernization Act of 2003, Medicare prescription drug benefit; reimportation of prescription drugs

H.R.810 , Medicare Regulatory and Contracting Reform Act of 2003, Medicare prescription drug benefit; rei of prescription drugs

S.1 , Prescription Drug and Medicare Improvement Act of 2003, Medicare prescription drug benefit; reimpor prescription drugs

17. House(s) of Congress and Federal agencies contacted

Check if None

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Angus, III, John W.	
Berman, Michael S.	
Champlin, Steven M.	
Duberstein, Kenneth M.	
Gandy, Henry M.	
Meyer, Daniel	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date **2/17/2004**

Printed Name and Title **John W. Angus, III - Senior Vice President & GC** _____ Pag

Registrant Name: The Duberstein Group, Inc.

Client Name: Pfizer Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

H.R.1 , Medicare Prescription Drug and Modernization Act of 2003, Drug reimportation

H.R.2427 , Pharmaceutical Market Access Act of 2003, Drug reimportation

H.R.2673 , Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2004, Drug reimportation

H.R.2769 , Save Our Seniors Act of 2003, Drug reimportation

S.1 , Prescription Drug and Medicare Improvement Act of 2003, Drug reimportation

S.1781 , Pharmaceutical Market Access Act of 2003, Drug reimportation

17. House(s) of Congress and Federal agencies contacted
House of Representatives

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Angus, III, John W.	
Berman, Michael S.	
Champlin, Steven M.	
Duberstein, Kenneth M.	
Gandy, Henry M.	
Meyer, Daniel	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 2/17/2004

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page